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1 It disproportionately affects underserved groups, including homeless people, people in poor housing or affected by poverty, people with problem drug use, and people born in countries with a high incidence of TB.
2 However, many cases are preventable with public health measures, and, when disease does occur, most people can be cured. This article summarises the updated recommendations on diagnosing, managing, and preventing TB from the National Institute for Health and Care Excellence (NICE) . 1 This guidance updates the 2011 clinical guideline 3 and incorporates the public health guidance on the identification and management of TB in under-served groups.
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Recommendations NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
See glossary for definitions of terms used.
Diagnosing latent infection
Box 1 provides general principles in identifying latent infection.
Children and young people who have been in close contact with people with infectious TB
• For children aged less than 2 years who have been in close contact with people with pulmonary or laryngeal TB, see figure 1⇓ . What's new in this guidance
• Increase in the upper age limit for testing and treatment for latent TB from 35 years to 65 years
• A Mantoux test is considered positive at an induration of ≥5 mm regardless of BCG history
• How to re-establish treatment for active or latent TB after interruptions by adverse events from drug treatment
Glossary of terms
Active tuberculosis disease-Infection with mycobacteria of the M tuberculosis complex where mycobacteria are growing and causing symptoms and signs of disease. This is distinct from latent infection, where mycobacteria are present but are not causing disease.
Directly observed therapy (DOT)-
A trained health professional, or responsible lay person supported by a trained health professional, provides the prescribed medication and watches the person swallow every dose.
High incidence country-More than 40 cases of TB per 100 000 people per year
5
Interferon γ release assay (IGRA)-A blood test used to diagnose latent TB (as an alternative or addition to tuberculin skin tests) based on detecting the response of white blood cells to TB antigens.
Latent infection-Infection with mycobacteria of the M tuberculosis complex where the bacteria are alive but not currently causing active disease.
Mantoux test-A type of tuberculin skin test in which tuberculin is injected intradermally. The injection site is examined for signs of a local skin reaction (induration) after 2-3 days. In any patient, regardless of BCG history, this guidance recommends that a Mantoux test is considered positive for TB infection if the transverse diameter of the area of induration is ≥5 mm.
Multidrug resistant TB-TB resistant to isoniazid and rifampicin, with or without any other resistance.
Nucleic acid amplification test (NAAT)-
A test to detect fragments of nucleic acid, allowing rapid and specific diagnosis of M tuberculosis directly from different clinical samples.
TB case manager-A named individual, appointed as soon as a patient becomes known to the TB service, who takes responsibility for ensuring that diagnostic investigations are completed and outcomes documented, that an appropriate treatment regimen is monitored and completed, and that contacts are identified, evaluated, and treated.
Treatment interruption-A break in the prescribed antituberculosis regimen for ≥2 weeks in the initial phase, or more than 20% of prescribed doses missed intermittently.
Box 1: Identification of latent infection [Updated recommendations 2016]
• Offer TB testing to close contacts of people with pulmonary or laryngeal TB, people who are immunocompromised and at high risk of TB, and new entrants from high incidence countries presenting for health care • If the NAAT for rifampicin resistance is positive −Continue infection control measures until pulmonary or laryngeal disease has been excluded −Manage treatment along with a multidisciplinary team with experience of managing multidrug resistant TB −Offer treatment with at least six drugs to which the mycobacterium is likely to be sensitive −Test for resistance to second line drugs.
[New recommendation 2016; based on the experience and opinion of the GDG]

Treating latent infection
• For people with evidence of latent TB, including those with HIV infection or those under 65 years old, offer either −Three months of isoniazid (with pyridoxine) and rifampicin, or −Six months of isoniazid (with pyridoxine).
[Updated recommendation 2016; based on network meta-analyses of very low quality randomised controlled trials, an original health economic model, and the experience and opinion of the GDG]
• Base the choice of regimen on the person's clinical circumstances. For example, offer three months of isoniazid (with pyridoxine) and rifampicin if hepatotoxicity is a concern, or offer six months of isoniazid (with pyridoxine) if interactions with rifamycins are a concern (such as in people with HIV or after a transplant • Minimise the number and duration of visits a person with TB makes to an outpatient department while they are still infectious
• Put people with suspected infectious or confirmed pulmonary or laryngeal TB who will remain in hospital in a single room. If this is not possible, keep the person's waiting times to a minimum. This may involve prioritising their care above that of other patients
• Do not admit people with suspected infectious or confirmed pulmonary TB to a ward containing people who are immunocompromised
• Explain to inpatients with suspected infectious or confirmed pulmonary or laryngeal TB that they will need to wear a face mask whenever they leave their room. Ask them to continue wearing it until they have had at least two weeks of treatment
• Offer patients advice on simple respiratory hygiene measures, such as covering the mouth and nose with a tissue when coughing or sneezing and disposing of the tissue in a waste basket
• For people deemed to be at high risk of multidrug resistance, provide care in a negative pressure room
• Staff and visitors should wear FFP3 face masks during contact with a person with suspected or known multidrug resistant TB while the person is thought to be infectious 
Box 6: Strategies to encourage people to follow their treatment plan [Updated recommendations 2016]
• Enhanced case management, including DOT
• Reminder letters, printed information, telephone calls, texts, and apps using an appropriate language
• Health education counselling and patient centred interviews
• Tailored health education booklets from quality sources
• Home visits
• Random urine tests and other monitoring (such as pill counts)
• Access to free TB treatment for everyone (irrespective of eligibility for other NHS care) and information about help with paying for prescriptions
• Social and psychological support (including cultural case management and broader social support)
• Advice and support for parents and carers 
Overcoming barriers
More routine use of NAATs means that laboratories may need to review their practices for TB diagnosis, as well as invest in the training and facilities required. Where this is not possible, it will be necessary to arrange partnerships with other centres for external testing.
The updated guidance also puts a greater emphasis on the role of "specialists," whether they are individual clinicians or the multidisciplinary team. This is particularly important for treatment of children, co-management of TB with other conditions, and the management of multidrug resistant TB. Partnerships with other centres or specialist advisory services (such as the national advisory service for multidrug-resistant TB currently provided by the British Thoracic Society (http:// forums.brit-thoracic.org.uk/ for further information)) may be necessary to ensure that specialist input is available for all patients.
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Guidelines into practice
Does the patient have signs, symptoms, or risk factors for TB, and, therefore, should diagnostic efforts be initiated?
Should infection control measures be initiated, and to what degree? Do rapid diagnostic tests for drug resistance need to be ordered?
How patients were involved in the creation of this article
Committee members involved in this guideline update included lay members who contributed to the formulation of the recommendations summarised here.
Further information on the guidance
Methods
The Guideline Development Group (GDG) and Service Delivery Group (SDG) followed standard National Institute for Health and Care Excellence (NICE) methods to produce this updated guidance. 7 8 The GDG included two infectious disease epidemiologists, a physician in global health and tuberculosis (TB), two general practitioners, two consultants in communicable disease control, two TB nurses, one respiratory pharmacist, two infectious diseases physicians, two respiratory physicians (one co-opted), one paediatrician, two medical microbiologists, and four patient or lay members. The SDG included two infectious disease epidemiologists, one infectious diseases physician, one director of public health, one consultant in public health, two respiratory physicians, one consultant in health protection, one consultant in communicable disease control, one TB nurse, one general practitioner, one community development officer, and three patient or lay members.
The GDG and SDG developed the review questions. To answer these questions, the NICE systematic reviewing team identified and analysed the clinical and health economic evidence. Meta-analysis, network meta-analysis, narrative analysis, and health economic modelling were undertaken when appropriate. GRADE methodology was also applied to develop quality ratings for the body of evidence. The development groups appraised and interpreted the evidence to develop the recommendations and research recommendations. A draft guideline, which went through a quality assurance process, was developed. The draft guideline was consulted on by a range of stakeholders who were invited to comment, and all comments were considered by the GDG when producing the final version of the guideline. All these versions, together with a suite of tools to help with implementation of the guidance (http://www.nice.org.uk/guidance/ng33/resources), are available from the NICE website (http://www.nice.org.uk). Further updates of the guidance will be produced as part of NICE's guideline development programme.
Available versions of this guidance
Future research
• In people with suspected TB, what is the relative clinical and cost effectiveness of universal and risk-based use of rapid nucleic acid amplification tests?
• Apart from culture, what other diagnostic tests or combinations of tests can establish an accurate diagnosis of active respiratory TB in children and young people with suspected active TB?
• For isoniazid-resistant TB, what is the most effective regimen for reducing mortality and morbidity?
• What effects does isolation have on the quality of life of people being treated for TB?
• For people with active, drug susceptible TB who experience treatment interruptions because of adverse events, particularly hepatotoxicity, what approach to re-establishing treatment most effectively reduces mortality and morbidity? 
